A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
- Conditions
- Cardiovascular Disease, ObesityTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-503659-88-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1800
Have obesity., Have established heart disease., Have history of unsuccessful dietary weight loss effort
have had the following within 90 days before screening: heart attack, stroke, a procedure to get blood flowing back into the heart, or been hospitalized for either congestive heart failure or sudden chest pain because of a blood clot in the heart, Have been taking weight loss drugs, including over-the-counter medications, within 90 days before screening, Have a self-reported change in body weight greater than 11 pounds within 90 days before screening., have undergone weight loss surgery (e.g. stomach stapling, lap banding) within 1 year before screening, Have Type 1 diabetes, Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2), Have had chronic or acute pancreatitis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method